Turning shareholder communications into meaningful engagement.

Few equity stories are harder to tell than a clinical biotech's. With investor communications spread across separate website, email and database systems, the company had limited visibility into who on its register was receiving and engaging with updates. Starpharma needed a more effective way to simplify complex milestones, engage shareholders beyond its largest investors, and gain clear insights into shareholder engagement and sentiment.

Since moving to InvestorHub in September 2025, Starpharma has run a milestone-packed year through one hub: new partnership agreements with Genentech and Radiopharm Theranostics, and a first-in-human Phase 1 study on track for H2 2026, supported by positive preclinical data and FDA alignment on the clinical pathway. Its lean, in-house IR team communicates every announcement to the full register and keeps an engaged shareholder base that continues to grow and outpaces similar market-cap peers.